Cargando…

Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis

AIMS/HYPOTHESIS: Whether sodium–glucose co-transporter 2 inhibitors (SGLT2is) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are cost-effective based solely on their cardiovascular and kidney benefits is unknown. We projected the health and economic outcomes due to myocardial infarction (M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morton, Jedidiah I., Marquina, Clara, Shaw, Jonathan E., Liew, Danny, Polkinghorne, Kevan R., Ademi, Zanfina, Magliano, Dianna J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947091/ https://www.ncbi.nlm.nih.gov/pubmed/36404375 http://dx.doi.org/10.1007/s00125-022-05832-0

Ejemplares similares

Long-term cost-effectiveness of implementing a lifestyle intervention during pregnancy to reduce the incidence of gestational diabetes and type 2 diabetes
por: Lloyd, Melanie, et al.
Publicado: (2023)

Projecting the Health and Economic Burden of Cardiovascular Disease Among People with Type 2 Diabetes, 2022–2031
por: Abushanab, Dina, et al.
Publicado: (2023)

The Cost-Effectiveness of Supplemental Carnosine in Type 2 Diabetes
por: Menon, Kirthi, et al.
Publicado: (2022)

Projected New-Onset Cardiovascular Disease by Socioeconomic Group in Australia
por: Hastings, Kaitlyn, et al.
Publicado: (2022)

Cost-Effectiveness of Eplerenone Compared to Usual Care in Patients With Chronic Heart Failure and NYHA Class II Symptoms, an Australian Perspective
por: Ademi, Zanfina, et al.
Publicado: (2016)

Diabetes Prevention and Treatment Strategies: Are we doing enough?
por: Backholer, Kathryn, et al.
Publicado: (2013)

Health and productivity burden of coronary heart disease in the working Indonesian population using life-table modelling
por: Uli, Regina E, et al.
Publicado: (2020)

Assessing the impact of smoking on the health and productivity of the working-age Indonesian population using modelling
por: Satyana, Regina P U, et al.
Publicado: (2020)

Integrating the Biology of Cardiovascular Disease into the Epidemiology of Economic Decision Modelling via Mendelian Randomisation
por: Ademi, Zanfina, et al.
Publicado: (2022)

Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease
por: Luo, Jing, et al.
Publicado: (2023)

The impact of diabetes on the productivity and economy of Bangladesh
por: Afroz, Afsana, et al.
Publicado: (2020)

Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study
por: Newman, Terri Victoria, et al.
Publicado: (2021)

Rate of decline in kidney function and known age-of-onset or duration of type 2 diabetes
por: Buyadaa, Oyunchimeg, et al.
Publicado: (2021)

FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND GLP1-RA IN OLDER ADULTS WITH TYPE 2 DIABETES
por: Patorno, Elisabetta, et al.
Publicado: (2019)

Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes
por: Chin, Ken Lee, et al.
Publicado: (2019)

Productivity-Adjusted Life-Years: A New Metric for Quantifying Disease Burden
por: Ademi, Zanfina, et al.
Publicado: (2021)

Burden of disease and productivity impact of Streptococcus suis infection in Thailand
por: Rayanakorn, Ajaree, et al.
Publicado: (2021)

Monitoring the Comparative Safety of SGLT2i vs GLP-1 RA in Older Adults With Type 2 Diabetes by Frailty Status
por: Kutz, Alexander, et al.
Publicado: (2021)

The effectiveness and cost effectiveness of dark chocolate consumption as prevention therapy in people at high risk of cardiovascular disease: best case scenario analysis using a Markov model
por: Zomer, Ella, et al.
Publicado: (2012)

Underprescription of SGLT2i and GLP-1 RA: CAREPRO-T2D (Cardiorenal Protection in Type 2 Diabetes) Cross-Sectional Study
por: Simões de Carvalho, Francisco, et al.
Publicado: (2023)

Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials: Perspective on GLP-1 RA and SGLT-2i therapies
por: Ludwig, Lisa, et al.
Publicado: (2020)

SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence
por: D'Marco, Luis, et al.
Publicado: (2021)

Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction
por: Trombara, Filippo, et al.
Publicado: (2023)

FRI648 GLP-1RA And SGLT2i Treatments May Show Improved Depression Metrics In Diabetes Treatment
por: Jain, Arad, et al.
Publicado: (2023)

Persistent disparities in diabetes medication receipt by socio‐economic disadvantage in Australia
por: Morton, Jedidiah I., et al.
Publicado: (2022)

Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages
por: Koike, Masao, et al.
Publicado: (2021)

Treatment costs for patients with Streptococcus suis infection in Northern Thailand: a hospital-based observational study of 14-year data
por: Rayanakorn, Ajaree, et al.
Publicado: (2023)

Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?
por: Belli, Martina, et al.
Publicado: (2022)

SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
por: Anson, Matthew, et al.
Publicado: (2023)

Use of Decision-Analytic Modelling to Assess the Cost-Effectiveness of Diagnostic Imaging of the Spine, Shoulder, and Knee: A Scoping Review
por: Docking, Sean, et al.
Publicado: (2023)

Reducing hip and non-vertebral fractures in institutionalised older adults by restoring inadequate intakes of protein and calcium is cost-saving
por: Baek, Yeji, et al.
Publicado: (2023)

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
por: Schernthaner, Guntram, et al.
Publicado: (2020)

Examining the factors contributing to the association between non-albuminuric CKD and a low rate of kidney function decline in diabetes
por: Buyadaa, Oyunchimeg, et al.
Publicado: (2022)

Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients
por: Du, Lixin, et al.
Publicado: (2022)

Estimating the benefits of obesity prevention on productivity: an Australian perspective
por: Menon, Kirthi, et al.
Publicado: (2022)

Cost Effectiveness of Antenatal Lifestyle Interventions for Preventing Gestational Diabetes and Hypertensive Disease in Pregnancy
por: Bailey, Cate, et al.
Publicado: (2020)

Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study
por: Knudsen, Jakob S., et al.
Publicado: (2020)

Associations of Chronic Kidney Disease Markers with Cognitive Function: A 12-Year Follow-Up Study
por: Sacre, Julian W., et al.
Publicado: (2019)

Cost–Utility of Angiotensin-Converting Enzyme Inhibitor-Based Treatment Compared With Thiazide Diuretic-Based Treatment for Hypertension in Elderly Australians Considering Diabetes as Comorbidity
por: Chowdhury, Enayet K., et al.
Publicado: (2015)

Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease
por: Shupo, Francis, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_94k8cs4oulc7j8epjlpvh61utk